Literature DB >> 21697304

Pilot study of FPPRGD2 for imaging α(v)β(3) integrin--how integral are integrins?

Peter L Choyke1.   

Abstract

Mittra et al (1) describe a new positron emission tomographic (PET) radiopharmaceutical, fluorine 18 ((18)F) 2-fl uoropropionyl labeled PEGylated dimeric RGD peptide (FPPRGD2), a marker of α(v)β(3) integrin expression, which they tested in fi ve healthy volunteers. No adverse events were encountered, and the biodistribution suggested both a renal and a hepatobiliary excretory route. This early safety testing paves the way for future studies of patients with cancer who are undergoing antiangiogenic therapies. (18)F-FPPRGD2 represents one of several integrin imaging agents that are moving closer to clinical reality.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21697304      PMCID： PMC3135879          DOI： 10.1148/radiol.11110740

Source DB:  PubMed          Journal:  Radiology        ISSN： 0033-8419            Impact factor:   11.105


  6 in total

1.  PET of αvbeta3-integrin and αvbeta5-integrin expression with 18F-fluciclatide for assessment of response to targeted therapy: ready for prime time?

Authors:  Ambros J Beer; Markus Schwaiger
Journal:  J Nucl Med       Date:  2011-02-14       Impact factor: 10.057

2.  Pilot pharmacokinetic and dosimetric studies of (18)F-FPPRGD2: a PET radiopharmaceutical agent for imaging α(v)β(3) integrin levels.

Authors:  Erik S Mittra; Michael L Goris; Andrei H Iagaru; Arash Kardan; Lindee Burton; Rhona Berganos; Edwin Chang; Shuanglong Liu; Bin Shen; Frederick T Chin; Xiaoyuan Chen; Sanjiv S Gambhir
Journal:  Radiology       Date:  2011-04-18       Impact factor: 11.105

3.  Monitoring tumor response to antiangiogenic sunitinib therapy with 18F-fluciclatide, an 18F-labeled αVbeta3-integrin and αV beta5-integrin imaging agent.

Authors:  Mark R Battle; Julian L Goggi; Lucy Allen; Jon Barnett; Matthew S Morrison
Journal:  J Nucl Med       Date:  2011-02-14       Impact factor: 10.057

Review 4.  Multimodality molecular imaging of tumor angiogenesis.

Authors:  Weibo Cai; Xiaoyuan Chen
Journal:  J Nucl Med       Date:  2008-06       Impact factor: 10.057

5.  Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients.

Authors:  Laura M Kenny; R Charles Coombes; Inger Oulie; Kaiyumars B Contractor; Matthew Miller; Terence J Spinks; Brian McParland; Pamela S Cohen; Ai-Min Hui; Carlo Palmieri; Safiye Osman; Matthias Glaser; David Turton; Adil Al-Nahhas; Eric O Aboagye
Journal:  J Nucl Med       Date:  2008-05-15       Impact factor: 10.057

6.  Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD.

Authors:  Roland Haubner; Wolfgang A Weber; Ambros J Beer; Eugenija Vabuliene; Daniel Reim; Mario Sarbia; Karl-Friedrich Becker; Michael Goebel; Rüdiger Hein; Hans-Jürgen Wester; Horst Kessler; Markus Schwaiger
Journal:  PLoS Med       Date:  2005-03-29       Impact factor: 11.069
  6 in total
  3 in total

1.  RGD PET: From Lesion Detection to Therapy Response Monitoring.

Authors:  Gang Niu; Xiaoyuan Chen
Journal:  J Nucl Med       Date:  2015-11-25       Impact factor: 10.057

2.  Positron emission tomography imaging of tumor angiogenesis and monitoring of antiangiogenic efficacy using the novel tetrameric peptide probe 64Cu-cyclam-RAFT-c(-RGDfK-)4.

Authors:  Zhao-Hui Jin; Takako Furukawa; Michael Claron; Didier Boturyn; Jean-Luc Coll; Toshimitsu Fukumura; Yasuhisa Fujibayashi; Pascal Dumy; Tsuneo Saga
Journal:  Angiogenesis       Date:  2012-05-29       Impact factor: 9.596

3.  Preclinical validations of [18F]FPyPEGCBT-c(RGDfK): a 18F-labelled RGD peptide prepared by ligation of 2-cyanobenzothiazole and 1,2-aminothiol to image angiogenesis.

Authors:  Didier J Colin; James A H Inkster; Stéphane Germain; Yann Seimbille
Journal:  EJNMMI Radiopharm Chem       Date:  2016-10-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.